Aggressive Trading Strategies

[bobkubecka]

HOMI FWIW Posted by: SSP
In reply to: None Date:5/19/2004 9:52:21 AM
Post #of 27171

MARK AHN NAMED CEO AND PRESIDENT OF HUDSON HEALTH SCIENCES Company Developing Novel Anti-Cancer Drug Licensed from Dana-Farber Cancer Institute South San Francisco (January 22, 2004) -- Hudson Health Sciences, Inc. , a development stage biopharmaceutical company headquartered in South San Francisco, California announced today the appointment of Mark J. Ahn, Ph.D. as Company president and chief executive officer. “We are extremely excited that Dr. Ahn has decided to join Hudson as its president and CEO,” said board member Dr. Michael Weiser. “His experience and leadership will be a critical factor in Hudson’s success and we are all confident that he will guide and grow the Company towards important achievements and milestones.” Prior to joining Hudson Health Sciences, Dr. Ahn was Vice President, Hematology at Genentech, Inc., where he was responsible for Rituxan®. While Dr. Ahn was with Genentech, Rituxan surpassed $1.0 billion in revenues and became the leading anti-cancer therapy in the US. Prior to Genentech, Dr. Ahn held a series of positions of increasing responsibility at Bristol-Myers Squibb Company, Amgen, Inc. and FMC Corporation in strategy, general management, sales and marketing, business development, and finance. Dr. Ahn received a BA in History and an MBA in Finance from Chaminade University. He was a graduate fellow in Economics at Essex University and has a Ph.D. in Business Administration from the University of South Australia. Dr. Ahn is also a Henry Crown Fellow at the Aspen Institute, co-founder of the Center for Non-Profit Leadership, and a member of the Board of Trustees for the MEDUNSA (Medical University of South Africa) Trust. He also served as an officer in the US Army. Hudson has licensed the exclusive worldwide rights to PT-523 from the Dana- Farber Cancer Institute. PT-523 is a novel antifolate drug with potential applications that include the treatment of certain cancers and autoimmune
�� Page 2
diseases. The compound was developed at the Dana-Farber Cancer Institute and the National Cancer Institute as part of a program to develop innovative anti-cancer products. Preliminary studies indicate PT-523 has several potential advantages over existing therapies for cancer, including increased targeting to tumor cells, better tolerability and a superior resistance profile. A key component of Hudson’s business strategy is to acquire global rights to additional product candidates in oncology and immunology while continuing to use its technology platform to develop and commercialize new products and line extensions. About Hudson Health Sciences Hudson Health Sciences, Inc. is a development stage biopharmaceutical company focused on acquiring, developing and commercializing innovative products for the treatment of important unmet medical needs, including cancer and immunological diseases. Hudson’s lead product candidate, PT-523 licensed from the Dana-Farber Cancer Institute, is a novel antifolate drug with potential applications including the treatment of certain cancers and autoimmune diseases. Additional information on Hudson Health Sciences can be found at www.hudson-health.com. ### Forward Looking Safe Harbor Statement: This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our pharmaceutical collaborator’s ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors described in our filings with the Securities and Exchange Commission.